TuisIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$33,17
Dagwisseling
$32,37 - $33,62
Jaarwisseling
$31,03 - $52,34
Markkapitalisasie
5,15 mjd USD
Gemiddelde volume
1,63 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 133,81 m | -7,21% |
Bedryfskoste | 259,28 m | -2,73% |
Netto inkomste | -140,48 m | 4,70% |
Netto winsgrens | -104,98 | -2,70% |
Wins per aandeel | -0,72 | 14,35% |
EBITDA | -145,68 m | -3,99% |
Effektiewe belastingkoers | 2,51% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,49 mjd | 11,10% |
Totale bates | 3,08 mjd | 5,01% |
Totale aanspreeklikheid | 2,42 mjd | -7,63% |
Totale ekwiteit | 662,47 m | — |
Uitstaande aandele | 157,90 m | — |
Prys om te bespreek | 7,90 | — |
Opbrengs op bates | -12,88% | — |
Opbrengs op kapitaal | -15,15% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -140,48 m | 4,70% |
Kontant van bedrywe | -114,99 m | -5,47% |
Kontant van beleggings | -340,80 m | -595,98% |
Kontant van finansiering | 496,05 m | 1 637,32% |
Netto kontantverandering | 40,61 m | 155,84% |
Beskikbare kontantvloei | -46,15 m | 46,55% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
927
